{{Drugbox
| verifiedrevid = 437154853
| IUPAC_name = 4-(7-bromo-5-methoxybenzofuran-2-yl)piperidine
| image = Brofaromine.svg

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = 98%
| metabolism =  
| elimination_half-life = 9-14 hours
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 63638-91-5
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 44571
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 40549
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 6WV4B8Q07H
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02560
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 160347

<!--Chemical data-->
| C=14 | H=16 | Br=1 | N=1 | O=2 
| molecular_weight = 310.186 g/mol
| smiles = Brc3cc(OC)cc1c3oc(c1)C2CCNCC2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C14H16BrNO2/c1-17-11-6-10-7-13(9-2-4-16-5-3-9)18-14(10)12(15)8-11/h6-9,16H,2-5H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = WZXHSWVDAYOFPE-UHFFFAOYSA-N
}}

'''Brofaromine''' (proposed brand name '''Consonar''') is a [[reversible inhibitor of monoamine oxidase A]] (RIMA) discovered by Ciba-Geigy.<ref>US Patent 4210655</ref> The compound was primarily researched in the treatment of [[Clinical depression|depression]] and [[anxiety]] but its development was dropped before it was brought to market.<ref name=Lotufo>{{cite journal |vauthors=Lotufo-Neto F, Trivedi M, Thase ME |title=Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression |journal=Neuropsychopharmacology |volume=20 |issue=3 |pages=226â€“47 |year=1999 |pmid=10063483 |doi=10.1016/S0893-133X(98)00075-X}} [http://www.nature.com/npp/journal/v20/n3/full/1395258a.html Free full text]</ref>

Brofaromine also acts as a [[serotonin reuptake inhibitor]], and its dual pharmacologic effects offered promise in the treatment of a wide spectrum of depressed patients while producing less severe [[anticholinergic]] side effects in comparison with older standard drugs like the [[tricyclic antidepressant]]s.

==Pharmacology==
Brofaromine is a [[reversible inhibitor of monoamine oxidase A]] (RIMA, a type of [[monoamine oxidase inhibitor]] (MAOI)) and acts on [[epinephrine]] (adrenaline), [[norepinephrine]] (noradrenaline), [[serotonin]], and [[dopamine]]. Unlike standard MAOIs, possible side effects do not include [[cardiovascular]] complications ([[hypertension]]) with [[encephalopathy]], [[Hepatotoxicity|liver toxicity]] or [[hyperthermia]].

==References==
{{Reflist|2}}

{{Antidepressants}}
{{Anxiolytics}}
{{Monoamine metabolism modulators}}

[[Category:Abandoned drugs]]
[[Category:Antidepressants]]
[[Category:Anxiolytics]]
[[Category:Monoamine oxidase inhibitors]]
[[Category:Reversible inhibitors of MAO-A]]
[[Category:Phenol ethers]]
[[Category:Organobromides]]
[[Category:Benzofurans]]
[[Category:Piperidines]]
[[Category:Serotonin reuptake inhibitors]]


{{nervous-system-drug-stub}}